# John B Porter

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8617706/publications.pdf

Version: 2024-02-01

| | | | |
|---|---|---|---|
| 199 papers | 11,609 citations | 19608 61 h-index | 32761 100 g-index |
| 200 all docs | 200 docs citations | 200 times ranked | 7289 citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia. Blood, 2006, 107, 3455-3462. | 0.6 | 636 |
| 2 | On T2* Magnetic Resonance and Cardiac Iron. Circulation, 2011, 123, 1519-1528. | 1.6 | 381 |
| 3 | Myocardial iron clearance during reversal of siderotic cardiomyopathy with intravenous desferrioxamine: a prospective study using T2* cardiovascular magnetic resonance. British Journal of Haematology, 2004, 127, 348-355. | 1.2 | 340 |
| 4 | Practical management of iron overload. British Journal of Haematology, 2001, 115, 239-252. | 1.2 | 317 |
| 5 | Cardiovascular Function and Treatment in Î²-Thalassemia Major. Circulation, 2013, 128, 281-308. | 1.6 | 301 |
| 6 | Oxidative stress and inflammation in iron-overloaded patients with ?-thalassaemia or sickle cell disease. British Journal of Haematology, 2006, 135, 254-263. | 1.2 | 260 |
| 7 | Tailoring iron chelation by iron intake and serum ferritin: the prospective EPIC study of deferasirox in 1744 patients with transfusion-dependent anemias. Haematologica, 2010, 95, 557-566. | 1.7 | 260 |
| 8 | Long-term outcome of continuous 24-hour deferoxamine infusion via indwelling intravenous catheters in high-risk Î²-thalassemia. Blood, 2000, 95, 1229-1236. | 0.6 | 259 |
| 9 | A randomised comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease. British Journal of Haematology, 2007, 136, 501-508. | 1.2 | 255 |
| 10 | Synthesis, physicochemical properties, and biological evaluation of N-substituted 2-alkyl-3-hydroxy-4(1H)-pyridinones: orally active iron chelators with clinical potential. Journal of Medicinal Chemistry, 1993, 36, 2448-2458. | 2.9 | 211 |
| 11 | Relative response of patients with myelodysplastic syndromes and other transfusionâ€dependent anaemias to deferasirox (ICL670): a 1â€yr prospective study. European Journal of Haematology, 2008, 80, 168-176. | 1.1 | 210 |
| 12 | Iron chelation with deferasirox in adult and pediatric patients with thalassemia major: efficacy and safety during 5 years' follow-up. Blood, 2011, 118, 884-893. | 0.6 | 181 |
| 13 | A Phase 3 Trial of Luspatercept in Patients with Transfusion-Dependent Î²-Thalassemia. New England Journal of Medicine, 2020, 382, 1219-1231. | 13.9 | 177 |
| 14 | Efficacy of deferasirox in reducing and preventing cardiac iron overload in Î²-thalassemia. Blood, 2010, 115, 2364-2371. | 0.6 | 168 |
| 15 | Effect of transfusional iron intake on response to chelation therapy in Î²-thalassemia major. Blood, 2008, 111, 583-587. | 0.6 | 161 |
| 16 | Value of sequential monitoring of left ventricular ejection fraction in the management of thalassemia major. Blood, 2004, 104, 263-269. | 0.6 | 156 |
| 17 | The Relationship of Intracellular Iron Chelation to the Inhibition and Regeneration of Human Ribonucleotide Reductase. Journal of Biological Chemistry, 1996, 271, 20291-20299. | 1.6 | 153 |
| 18 | Quantification of Non-Transferrin-Bound Iron in the Presence of Unsaturated Transferrin. Analytical Biochemistry, 1999, 273, 212-220. | 1.1 | 150 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | Desferrioxamine ototoxicity: evaluation of risk factors in thalassaemic patients and guidelines for safe dosage. British Journal of Haematology, 1989, 73, 403-409. | 1.2 | 144 |
| 20 | Biopsy-based calibration of T2* magnetic resonance for estimation of liver iron concentration and comparison with R2 Ferriscan. Journal of Cardiovascular Magnetic Resonance, 2014, 16, 40. | 1.6 | 143 |
| 21 | Microvesicles in haemoglobinopathies offer insights into mechanisms of hypercoagulability, haemolysis and the effects of therapy. British Journal of Haematology, 2008, 142, 126-135. | 1.2 | 142 |
| 22 | Noncontrast myocardial T<sub>1</sub> mapping using cardiovascular magnetic resonance for iron overload. Journal of Magnetic Resonance Imaging, 2015, 41, 1505-1511. | 1.9 | 139 |
| 23 | A direct method for quantification of non-transferrin-bound iron. Analytical Biochemistry, 1990, 186, 320-323. | 1.1 | 136 |
| 24 | Nature of non-transferrin-bound iron: studies on iron citrate complexes and thalassemic sera. Journal of Biological Inorganic Chemistry, 2007, 13, 57-74. | 1.1 | 134 |
| 25 | Prospective evaluation of patient-reported outcomes during treatment with deferasirox or deferoxamine for iron overload in patients with Î²-thalassemia. Clinical Therapeutics, 2007, 29, 909-917. | 1.1 | 123 |
| 26 | Deferasirox for up to 3 years leads to continued improvement of myocardial T2* in patients with Â-thalassemia major. Haematologica, 2012, 97, 842-848. | 1.7 | 122 |
| 27 | Consequences and management of iron overload in sickle cell disease. Hematology American Society of Hematology Education Program, 2013, 2013, 447-456. | 0.9 | 122 |
| 28 | Deferasirox reduces iron overload significantly in nontransfusion-dependent thalassemia: 1-year results from a prospective, randomized, double-blind, placebo-controlled study. Blood, 2012, 120, 970-977. | 0.6 | 115 |
| 29 | Novel 3-hydroxy-2(1H)-pyridinones. Synthesis, iron(III)-chelating properties and biological activity. Journal of Medicinal Chemistry, 1990, 33, 1749-1755. | 2.9 | 112 |
| 30 | Leukocyte activity in the microcirculation of the leg in patients with chronic venous disease. Journal of Vascular Surgery, 1997, 26, 265-273. | 0.6 | 106 |
| 31 | Determination of non-transferrin-bound iron in genetic hemochromatosis using a new HPLC-based method. Journal of Hepatology, 2000, 32, 727-733. | 1.8 | 103 |
| 32 | Efficacy and safety of deferasirox doses of >30â€ƒmg/kg per d in patients with transfusionâ€dependent anaemia and iron overload. British Journal of Haematology, 2009, 147, 752-759. | 1.2 | 101 |
| 33 | Eltrombopag: a powerful chelator of cellular or extracellular iron(III) alone or combined with a second chelator. Blood, 2017, 130, 1923-1933. | 0.6 | 98 |
| 34 | A 1-year randomized controlled trial of deferasirox vs deferoxamine for myocardial iron removal in Î²-thalassemia major (CORDELIA). Blood, 2014, 123, 1447-1454. | 0.6 | 97 |
| 35 | A paradigm shift on beta-thalassaemia treatment: How will we manage this old disease with new therapies?. Blood Reviews, 2018, 32, 300-311. | 2.8 | 95 |
| 36 | Results of an international round robin for the quantification of serum non-transferrin-bound iron: Need for defining standardization and a clinically relevant isoform. Analytical Biochemistry, 2005, 341, 241-250. | 1.1 | 93 |

| # | Article | IF | Citations |
|---|---|---|---|
| 37 | The Pathophysiology of Transfusional Iron Overload. Hematology/Oncology Clinics of North America, 2014, 28, 683-701. | 0.9 | 91 |
| 38 | Betibeglogene Autotemcel Gene Therapy for Nonâ€“Î² <sup>0</sup> /Î² <sup>0</sup> Genotype Î²-Thalassemia. New England Journal of Medicine, 2022, 386, 415-427. | 13.9 | 91 |
| 39 | Concepts and goals in the management of transfusional iron overload. American Journal of Hematology, 2007, 82, 1136-1139. | 2.0 | 86 |
| 40 | A Risk-Benefit Assessment of Iron-Chelation Therapy. Drug Safety, 1997, 17, 407-421. | 1.4 | 85 |
| 41 | Normalized left ventricular volumes and function in thalassemia major patients with normal myocardial iron. Journal of Magnetic Resonance Imaging, 2007, 25, 1147-1151. | 1.9 | 81 |
| 42 | Chelation use and iron burden in North American and British thalassemia patients: a report from the Thalassemia Longitudinal Cohort. Blood, 2012, 119, 2746-2753. | 0.6 | 78 |
| 43 | Guidelines on red cell transfusion in sickle cell disease. Part I: principles and laboratory aspects. British Journal of Haematology, 2017, 176, 179-191. | 1.2 | 76 |
| 44 | Second international round robin for the quantification of serum non-transferrin-bound iron and labile plasma iron in patients with iron-overload disorders. Haematologica, 2016, 101, 38-45. | 1.7 | 74 |
| 45 | Left ventricular diastolic function compared with T2* cardiovascular magnetic resonance for early detection of myocardial iron overload in thalassemia major. Journal of Magnetic Resonance Imaging, 2005, 22, 229-233. | 1.9 | 73 |
| 46 | Improvement in Liver Pathology of Patients With Î²-Thalassemia Treated With Deferasirox for at Least 3 Years. Gastroenterology, 2011, 141, 1202-1211.e3. | 0.6 | 73 |
| 47 | Pharmacokinetics, Metabolism, and Disposition of Deferasirox in Î²-Thalassemic Patients with Transfusion-Dependent Iron Overload Who Are at Pharmacokinetic Steady State. Drug Metabolism and Disposition, 2010, 38, 808-816. | 1.7 | 72 |
| 48 | Continued improvement in myocardial T2* over two years of deferasirox therapy in Â-thalassemia major patients with cardiac iron overload. Haematologica, 2011, 96, 48-54. | 1.7 | 70 |
| 49 | The metabolites of nitric oxide in sickle-cell disease. British Journal of Haematology, 1995, 91, 834-837. | 1.2 | 69 |
| 50 | Combined chelation therapy with deferasirox and deferoxamine in thalassemia. Blood Cells, Molecules, and Diseases, 2013, 50, 99-104. | 0.6 | 69 |
| 51 | Design, Synthesis, and Evaluation of Novel 2-Substituted 3-Hydroxypyridin-4-ones:Â Structureâ^'Activity Investigation of Metalloenzyme Inhibition by Iron ChelatorsÂ§. Journal of Medicinal Chemistry, 2002, 45, 631-639. | 2.9 | 67 |
| 52 | Inflammation and oxidant-stress in Â-thalassemia patients treated with iron chelators deferasirox (ICL670) or deferoxamine: an ancillary study of the Novartis CICL670A0107 trial. Haematologica, 2008, 93, 817-825. | 1.7 | 67 |
| 53 | Longâ€term safety and efficacy of deferasirox (Exjade<sup>Â®</sup>) for up to 5â€ƒyears in transfusional ironâ€overloaded patients with sickle cell disease. British Journal of Haematology, 2011, 154, 387-397. | 1.2 | 67 |
| 54 | Effects of deferasirox-deferoxamine on myocardial and liver iron in patients with severe transfusional iron overload. Blood, 2015, 125, 3868-3877. | 0.6 | 67 |

| # | Article | IF | Citations |
|---|---|---|---|
| 55 | New filmâ€coated tablet formulation of deferasirox is well tolerated in patients with thalassemia or lowerâ€risk MDS: Results of the randomized, phase II ECLIPSE study. American Journal of Hematology, 2017, 92, 420-428. | 2.0 | 66 |
| 56 | Deferasirox effectively reduces iron overload in non-transfusion-dependent thalassemia (NTDT) patients: 1-year extension results from the THALASSA study. Annals of Hematology, 2013, 92, 1485-1493. | 0.8 | 64 |
| 57 | Subcellular distribution of desferrioxamine and hydroxypyridin-4-one chelators in K562 cells affects chelation of intracellular iron pools. British Journal of Haematology, 1993, 85, 393-400. | 1.2 | 63 |
| 58 | Iron chelation therapy with deferasirox in patients with aplastic anemia: a subgroup analysis of 116 patients from the EPIC trial. Blood, 2010, 116, 2448-2454. | 0.6 | 63 |
| 59 | Iron chelation adherence to deferoxamine and deferasirox in thalassemia. American Journal of Hematology, 2011, 86, 433-436. | 2.0 | 63 |
| 60 | The Environment of the Lipoxygenase Iron Binding Site Explored with Novel Hydroxypyridinone Iron Chelators. Journal of Biological Chemistry, 1996, 271, 7965-7972. | 1.6 | 62 |
| 61 | Pathophysiology of Transfusional Iron Overload: Contrasting Patterns in Thalassemia Major and Sickle Cell Disease. Hemoglobin, 2009, 33, S37-S45. | 0.4 | 62 |
| 62 | Prevalence and distribution of iron overload in patients with transfusionâ€dependent anemias differs across geographic regions: results from the <scp>CORDELIA</scp> study. European Journal of Haematology, 2015, 95, 244-253. | 1.1 | 61 |
| 63 | Optimizing iron chelation strategies in Î²-thalassaemia major. Blood Reviews, 2009, 23, S3-S7. | 2.8 | 59 |
| 64 | Mechanisms for the shuttling of plasma non-transferrin-bound iron (NTBI) onto deferoxamine by deferiprone. Translational Research, 2010, 156, 55-67. | 2.2 | 59 |
| 65 | Red blood cell-derived microparticles: An overview. Blood Cells, Molecules, and Diseases, 2016, 59, 134-139. | 0.6 | 58 |
| 66 | Deferoxamine pharmacokinetics. Seminars in Hematology, 2001, 38, 63-68. | 1.8 | 56 |
| 67 | Patient-Reported Outcomes of Deferasirox (ExjadeÂ®, ICL670) versus Deferoxamine in Sickle Cell Disease Patients with Transfusional Hemosiderosis. Acta Haematologica, 2008, 119, 133-141. | 0.7 | 56 |
| 68 | Hepcidin is suppressed by erythropoiesis in hemoglobin E Î²-thalassemia and Î²-thalassemia trait. Blood, 2015, 125, 873-880. | 0.6 | 56 |
| 69 | Risk factors and mortality associated with an elevated tricuspid regurgitant jet velocity measured by Doppler-echocardiography in thalassemia: a Thalassemia Clinical Research Network report. Blood, 2011, 118, 3794-3802. | 0.6 | 55 |
| 70 | Mechanisms of plasma nonâ€transferrin bound iron generation: insights from comparing transfused diamond blackfan anaemia with sickle cell and thalassaemia patients. British Journal of Haematology, 2014, 167, 692-696. | 1.2 | 54 |
| 71 | Myocardial tissue characterization and the role of chronic anemia in sickle cell cardiomyopathy. Journal of Magnetic Resonance Imaging, 2007, 26, 564-568. | 1.9 | 52 |
| 72 | Health-Related Quality of Life, Treatment Satisfaction, Adherence and Persistence inÎ²-Thalassemia and Myelodysplastic Syndrome Patients with Iron Overload Receiving Deferasirox: Results from the EPIC Clinical Trial. Anemia, 2012, 2012, 1-10. | 0.5 | 52 |

| # | Article | IF | Citations |
|---|---|---|---|
| 73 | Iron chelation therapy in thalassemia major: A systematic review with meta-analyses of 1520 patients included on randomized clinical trials. Blood Cells, Molecules, and Diseases, 2011, 47, 166-175. | 0.6 | 50 |
| 74 | Defining serum ferritin thresholds to predict clinically relevant liver iron concentrations for guiding deferasirox therapy when <scp>MRI</scp> is unavailable in patients with nonâ€transfusionâ€dependent thalassaemia. British Journal of Haematology, 2015, 168, 284-290. | 1.2 | 50 |
| 75 | Cellular zinc content is a major determinant of iron chelatorâ€“induced apoptosis of thymocytes. Blood, 2001, 98, 3831-3839. | 0.6 | 49 |
| 76 | The challenges of adherence and persistence with iron chelation therapy. International Journal of Hematology, 2011, 94, 453-460. | 0.7 | 49 |
| 77 | Cross-Talk between Available Guidelines for the Management of Patients with Beta-Thalassemia Major. Acta Haematologica, 2013, 130, 64-73. | 0.7 | 49 |
| 78 | Hematologic responses in patients with aplastic anemia treated with deferasirox: a post hoc analysis from the EPIC study. Haematologica, 2013, 98, 1045-1048. | 1.7 | 49 |
| 79 | Iron Overload in Thalassemia and Related Conditions: Therapeutic Goals and Assessment of Response to Chelation Therapies. Hematology/Oncology Clinics of North America, 2010, 24, 1109-1130. | 0.9 | 48 |
| 80 | A phase 2 study of the safety, tolerability, and pharmacodynamics of FBS0701, a novel oral iron chelator, in transfusional iron overload. Blood, 2012, 119, 3263-3268. | 0.6 | 48 |
| 81 | Safety and efficacy of pegylated interferon Â-2a and ribavirin for the treatment of hepatitis C in patients with thalassemia. Haematologica, 2008, 93, 1247-1251. | 1.7 | 47 |
| 82 | Treatment of heart failure in adults with thalassemia major: response in patients randomised to deferoxamine with or without deferiprone. Journal of Cardiovascular Magnetic Resonance, 2013, 15, 38. | 1.6 | 47 |
| 83 | New insights into transfusion-related iron toxicity: Implications for the oncologist. Critical Reviews in Oncology/Hematology, 2016, 99, 261-271. | 2.0 | 46 |
| 84 | The efficacy of an iron chelator (CP94) in increasing cellular protoporphyrin IX following intravesical 5-aminolaevulinic acid administration: an in vivo study. Journal of Photochemistry and Photobiology B: Biology, 1997, 38, 114-122. | 1.7 | 45 |
| 85 | Protecting vulnerable patients with inherited anaemias from unnecessary death during the COVIDâ€19 pandemic. British Journal of Haematology, 2020, 189, 635-639. | 1.2 | 45 |
| 86 | Sustained improvements in myocardial T2* over 2 years in severely ironâ€overloaded patients with beta thalassemia major treated with deferasirox or deferoxamine. American Journal of Hematology, 2015, 90, 91-96. | 2.0 | 43 |
| 87 | Iron overload across the spectrum of nonâ€transfusionâ€dependent thalassaemias: role of erythropoiesis, splenectomy and transfusions. British Journal of Haematology, 2017, 176, 288-299. | 1.2 | 43 |
| 88 | Separation and identification of desferrioxamine and its iron chelating metabolites by high-performance liquid chromatography and fast atom bombardment mass spectrometry: Choice of complexing agent and application to biological fluids. Analytical Biochemistry, 1990, 187, 212-219. | 1.1 | 42 |
| 89 | Symptoms of depression and anxiety in patients with thalassemia: Prevalence and correlates in the thalassemia longitudinal cohort. American Journal of Hematology, 2010, 85, 802-805. | 2.0 | 42 |
| 90 | Sudden exertional death in sickle cell trait: Figure 1. British Journal of Sports Medicine, 2012, 46, 312-314. | 3.1 | 42 |

| # | Article | IF | Citations |
|---|---|---|---|
| 91 | Monitoring chelation therapy to achieve optimal outcome in the treatment of thalassaemia. , 2002, 15, 329-329. | | 42 |
| 92 | Sildenafil therapy in thalassemia patients with Doppler-defined risk of pulmonary hypertension. Haematologica, 2013, 98, 1359-1367. | 1.7 | 40 |
| 93 | Hepcidin and iron species distribution inside the first-trimester human gestational sac. Molecular Human Reproduction, 2011, 17, 227-232. | 1.3 | 38 |
| 94 | A phase 1 dose-escalation study: safety, tolerability, and pharmacokinetics of FBS0701, a novel oral iron chelator for the treatment of transfusional iron overload. Haematologica, 2011, 96, 521-525. | 1.7 | 37 |
| 95 | Calibration of myocardial T2 and T1 against iron concentration. Journal of Cardiovascular Magnetic Resonance, 2014, 16, 62. | 1.6 | 36 |
| 96 | Evaluation of New Iron Chelators for Clinical Use. Acta Haematologica, 1996, 95, 13-25. | 0.7 | 35 |
| 97 | Relation of myocardial T2* to right ventricular function in thalassaemia major. European Heart Journal, 2010, 31, 1648-1654. | 1.0 | 35 |
| 98 | Facilitated uptake of zinc into human erythrocytes. Biochemical Pharmacology, 1990, 39, 1005-1012. | 2.0 | 34 |
| 99 | Lessons from Preclinical and Clinical Studies with 1,2-Diethyl-3-Hydroxypyridin-4-One, CP94 and Related Compounds. Advances in Experimental Medicine and Biology, 1994, 356, 361-370. | 0.8 | 34 |
| 100 | Structure-Function Investigation of the Interaction of 1- and 2-Substituted 3-Hydroxypyridin-4-ones with 5-Lipoxygenase and Ribonucleotide Reductase. Journal of Biological Chemistry, 2001, 276, 48814-48822. | 1.6 | 33 |
| 101 | On myocardial siderosis and left ventricular dysfunction in hemochromatosis. Journal of Cardiovascular Magnetic Resonance, 2013, 15, 24. | 1.6 | 32 |
| 102 | Raised Neutrophil Phospholipase A2 Activity and Defective Priming of NADPH Oxidase and Phospholipase A2 in Sickle Cell Disease. Blood, 1998, 91, 3423-3429. | 0.6 | 31 |
| 103 | Simplified flow cytometric method for fetal hemoglobin containing red blood cells. Cytometry, 2000, 42, 389-393. | 1.8 | 31 |
| 104 | Oral iron chelators: Prospects for future development. European Journal of Haematology, 1989, 43, 271-285. | 1.1 | 31 |
| 105 | Results of Long Term Iron Chelation Treatment with Deferoxamine. Advances in Experimental Medicine and Biology, 2002, 509, 91-125. | 0.8 | 30 |
| 106 | Synergistic intracellular iron chelation combinations: mechanisms and conditions for optimizing iron mobilization. British Journal of Haematology, 2015, 170, 874-883. | 1.2 | 29 |
| 107 | Limitations of serum ferritin to predict liver iron concentration responses to deferasirox therapy in patients with transfusionâ€dependent thalassaemia. European Journal of Haematology, 2017, 98, 280-288. | 1.1 | 29 |
| 108 | Disparity in the management of iron overload between patients with sickle cell disease and thalassemia who received transfusions. Transfusion, 2008, 48, 1971-1980. | 0.8 | 28 |

| # | Article | IF | Citations |
|---|---|---|---|
| 109 | Response of iron overload to deferasirox in rare transfusionâ€dependent anaemias: equivalent effects on serum ferritin and labile plasma iron for haemolytic or production anaemias. European Journal of Haematology, 2011, 87, 338-348. | 1.1 | 28 |
| 110 | Intravenous iron preparations transiently generate non-transferrin-bound iron from two proposed pathways. Haematologica, 2021, 106, 2885-2896. | 1.7 | 28 |
| 111 | A novel method for non-transferrin-bound iron quantification by chelatable fluorescent beads based on flow cytometry. Biochemical Journal, 2014, 463, 351-362. | 1.7 | 27 |
| 112 | Utility of labile plasma iron and transferrin saturation in addition to serum ferritin as iron overload markers in different underlying anemias before and after deferasirox treatment. European Journal of Haematology, 2016, 96, 19-26. | 1.1 | 27 |
| 113 | Deferasirox: An effective once-daily orally active iron chelator. Drugs of Today, 2006, 42, 623. | 0.7 | 27 |
| 114 | Consumption of a green tea extractâ€“curcumin drink decreases blood urea nitrogen and redox iron in Î²-thalassemia patients. Food and Function, 2020, 11, 932-943. | 2.1 | 26 |
| 115 | Deferoxamine pharmacokinetics. Seminars in Hematology, 2001, 38, 63-68. | 1.8 | 26 |
| 116 | Beyond transfusion therapy: new therapies in thalassemia including drugs, alternate donor transplant, and gene therapy. Hematology American Society of Hematology Education Program, 2018, 2018, 361-370. | 0.9 | 25 |
| 117 | Detection of metallic cobalt and chromium liver deposition following failed hip replacement using T2* and R2 magnetic resonance. Journal of Cardiovascular Magnetic Resonance, 2016, 18, 29. | 1.6 | 24 |
| 118 | Optimising iron chelation therapy with deferasirox for non-transfusion-dependent thalassaemia patients: 1-year results from the THETIS study. Blood Cells, Molecules, and Diseases, 2016, 57, 23-29. | 0.6 | 24 |
| 119 | Oneâ€year results from a prospective randomized trial comparing phlebotomy with deferasirox for the treatment of iron overload in pediatric patients with thalassemia major following curative stem cell transplantation. Pediatric Blood and Cancer, 2017, 64, 188-196. | 0.8 | 24 |
| 120 | Monitoring chelation therapy to achieve optimal outcome in the treatment of thalassaemia. Best Practice and Research in Clinical Haematology, 2002, 15, 329-68. | 0.7 | 24 |
| 121 | Ultrafast Magnetic Resonance Imaging for Iron Quantification in Thalassemia Participants in the Developing World. Circulation, 2016, 134, 432-434. | 1.6 | 23 |
| 122 | Improved Myocardial T2* in Transfusion Dependent Anemias Receiving ICL670 (Deferasirox).. Blood, 2005, 106, 3600-3600. | 0.6 | 23 |
| 123 | Dysregulated arginine metabolism and cardiopulmonary dysfunction in patients with thalassaemia. British Journal of Haematology, 2015, 169, 887-898. | 1.2 | 22 |
| 124 | The use of skin Fe levels as a surrogate marker for organ Fe levels, to monitor treatment in cases of iron overload. Physics in Medicine and Biology, 2000, 45, 1387-1396. | 1.6 | 21 |
| 125 | Prospective study of histomorphometry, biochemical bone markers and bone densitometric response to pamidronate in Î²â€thalassaemia presenting with osteopeniaâ€osteoporosis syndrome. British Journal of Haematology, 2012, 159, 462-471. | 1.2 | 21 |
| 126 | Decrement in Cellular Iron and Reactive Oxygen Species, and Improvement of Insulin Secretion in a Pancreatic Cell Line Using Green Tea Extract. Pancreas, 2019, 48, 636-643. | 0.5 | 21 |

| # | Article | IF | Citations |
|---|---|---|---|
| 127 | Which Psychosocial Factors are Related to Chelation Adherence in Thalassemia? A Systematic Review. Hemoglobin, 2010, 34, 305-321. | 0.4 | 20 |
| 128 | Transfusion and Chelation Practices in Sickle Cell Disease: A Regional Perspective. Pediatric Hematology and Oncology, 2011, 28, 124-133. | 0.3 | 20 |
| 129 | Residual erythropoiesis protects against myocardial hemosiderosis in transfusion-dependent thalassemia by lowering labile plasma iron via transient generation of apotransferrin. Haematologica, 2017, 102, 1640-1649. | 1.7 | 18 |
| 130 | Timed non-transferrin bound iron determinations probe the origin of chelatable iron pools during deferiprone regimens and predict chelation response. Haematologica, 2012, 97, 835-841. | 1.7 | 17 |
| 131 | Approaching low liver iron burden in chelated patients with nonâ€transfusionâ€dependent thalassemia: the safety profile of deferasirox. European Journal of Haematology, 2014, 92, 521-526. | 1.1 | 17 |
| 132 | Clinical and methodological factors affecting non-transferrin-bound iron values using a novel fluorescent bead assay. Translational Research, 2016, 177, 19-30.e5. | 2.2 | 17 |
| 133 | Iron Chelator Design. Advances in Experimental Medicine and Biology, 1994, 356, 343-349. | 0.8 | 17 |
| 134 | A Phase II Study with ICL670 (ExjadeÂ®), a Once-Daily Oral Iron Chelator, in Patients with Various Transfusion-Dependent Anemias and Iron Overload.. Blood, 2004, 104, 3193-3193. | 0.6 | 17 |
| 135 | Geographical variations in current clinical practice on transfusions and iron chelation therapy across various transfusion-dependent anaemias. Blood Transfusion, 2013, 11, 108-22. | 0.3 | 17 |
| 136 | Deferasirox demonstrates a doseâ€dependent reduction in liver iron concentration and consistent efficacy across subgroups of nonâ€transfusionâ€dependent thalassemia patients. American Journal of Hematology, 2013, 88, 503-506. | 2.0 | 16 |
| 137 | Right ventricular volumes and function in thalassemia major patients in the absence of myocardial iron overload. Journal of Cardiovascular Magnetic Resonance, 2010, 12, 24. | 1.6 | 15 |
| 138 | Efficacy and safety of iron-chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with nontransfusion-dependent thalassemia syndromes. Drug Design, Development and Therapy, 2016, Volume 10, 4073-4078. | 2.0 | 15 |
| 139 | Non-invasive MRI biomarkers for the early assessment of iron overload in a humanized mouse model of Î²-thalassemia. Scientific Reports, 2017, 7, 43439. | 1.6 | 15 |
| 140 | Patient-reported outcomes from a randomized phase II study of the deferasirox film-coated tablet in patients with transfusion-dependent anemias. Health and Quality of Life Outcomes, 2018, 16, 216. | 1.0 | 15 |
| 141 | Anti-Platelet Aggregation and Anti-Cyclooxygenase Activities for a Range of Coffee Extracts (Coffea) Tj ETQq1 1 0.784314 rgBT /Over | 1.7 | 15 |
| 142 | Development of a new disease severity scoring system for patients with non-transfusion-dependent thalassemia. European Journal of Internal Medicine, 2016, 28, 91-96. | 1.0 | 14 |
| 143 | Post-mortem study of the association between cardiac iron and fibrosis in transfusion dependent anaemia. Journal of Cardiovascular Magnetic Resonance, 2016, 19, 36. | 1.6 | 14 |
| 144 | Effect of Deferasirox (ExjadeÂ®) on Labile Plasma Iron Levels in Heavily Iron-Overloaded Patients with Transfusion-Dependent Anemias Enrolled in the Large-Scale, Prospective 1-Year EPIC Trial. Blood, 2008, 112, 3881-3881. | 0.6 | 14 |

| # | Article | IF | Citations |
|---|---|---|---|
| 145 | Oral ferroportin inhibitor vamifeport for improving iron homeostasis and erythropoiesis in Î²-thalassemia: current evidence and future clinical development. Expert Review of Hematology, 2021, 14, 633-644. | 1.0 | 13 |
| 146 | Impact of Compliance, Ferritin and LIC on Long-Term Trends in Myocardial T2* with Deferasirox. Blood, 2008, 112, 116-116. | 0.6 | 13 |
| 147 | Interaction of Transfusion and Iron Chelation in Thalassemias. Hematology/Oncology Clinics of North America, 2018, 32, 247-259. | 0.9 | 12 |
| 148 | Efficacy and Safety of Deferasirox (ExjadeÂ®) in Reducing Cardiac Iron in Patients with Î²-Thalassemia Major: Results from the Cardiac Substudy of the EPIC Trial. Blood, 2008, 112, 3873-3873. | 0.6 | 12 |
| 149 | A Decade Follow-up of a Thalassemia Major (TM) Cohort Monitored by Cardiac Magnetic Resonance Imaging (CMR): Significant Reduction In Patients with Cardiac Iron and In Total Mortality. Blood, 2010, 116, 1011-1011. | 0.6 | 12 |
| 150 | Cardiac T2* magnetic resonance for prediction of cardiac complications in thalassemia major. Journal of Cardiovascular Magnetic Resonance, 2009, 11, . | 1.6 | 11 |
| 151 | Deferasiroxâ€"current knowledge and future challenges. Annals of the New York Academy of Sciences, 2010, 1202, 87-93. | 1.8 | 11 |
| 152 | High index of suspicion for early diagnosis of alendronateâ€induced stage zero osteonecrosis of jaw in thalassaemia major. British Journal of Haematology, 2014, 166, 292-294. | 1.2 | 11 |
| 153 | Guidelines for the monitoring and management of iron overload in patients with haemoglobinopathies and rare anaemias. British Journal of Haematology, 2022, 196, 336-350. | 1.2 | 11 |
| 154 | Deferasirox: An Update. Hemoglobin, 2009, 33, S70-S75. | 0.4 | 9 |
| 155 | Effect of a novel oral active iron chelator: 1-(N-acetyl-6-aminohexyl)-3-hydroxy-2-methylpyridin-4-one (CM1) in iron-overloaded and non-overloaded mice. Asian Pacific Journal of Tropical Medicine, 2014, 7, S155-S161. | 0.4 | 9 |
| 156 | Psychological Factors Associated with Episodic Chelation Adherence in Thalassemia. Hemoglobin, 2018, 42, 30-36. | 0.4 | 9 |
| 157 | MRI Evidence of Cardiac Iron Accumulation in Myelodysplasia and Unusual Anaemias.. Blood, 2006, 108, 1553-1553. | 0.6 | 9 |
| 158 | Efficacy and Safety of Deferasirox (ExjadeÂ®) in Preventing Cardiac Iron Overload in Î²-Thalassemia Patients with Normal Baseline Cardiac Iron: Results from the Cardiac Substudy of the EPIC Trial. Blood, 2008, 112, 3874-3874. | 0.6 | 9 |
| 159 | Efficacy and Safety of Deferasirox (ExjadeÂ®) with up to 4.5 Years of Treatment in Patients with Thalassemia Major: A Pooled Analysis. Blood, 2008, 112, 5411-5411. | 0.6 | 9 |
| 160 | Deferiprone Is Associated with Lower Serum Ferritin (SF) Relative to Liver Iron Concentration (LIC) Than Deferoxamine and Deferasirox- Implications for Clinical Practice. Blood, 2010, 116, 4246-4246. | 0.6 | 9 |
| 161 | Ethical Issues and Risk/Benefit Assessment of Iron Chelation Therapy: Advances with Deferiprone/deferoxamine Combinations and Concerns about the Safety, Efficacy and Costs of Deferasirox [Kontoghiorghes GJ, Hemoglobin 2008; 32(1â€"2):1â€"15.]. Hemoglobin, 2008, 32, 601-607. | 0.4 | 8 |
| 162 | Blood Transfusion: Quality and Safety Issues in Thalassemia, Basic Requirements and New Trends. Hemoglobin, 2009, 33, S28-S36. | 0.4 | 8 |

| # | Article | IF | Citations |
|---|---|---|---|
| 163 | Iron chelation therapy for non-transfusion-dependent thalassemia (NTDT): A status quo. Blood Cells, Molecules, and Diseases, 2014, 52, 88-90. | 0.6 | 8 |
| 164 | 6-Alkoxymethyl-3-hydroxy-4H-pyranones: potential ligands for cell-labelling with indium. European Journal of Nuclear Medicine and Molecular Imaging, 1999, 26, 1400-1406. | 3.3 | 7 |
| 165 | Calibration of myocardial iron concentration against T2-star Cardiovascular Magnetic Resonance. Journal of Cardiovascular Magnetic Resonance, 2009, 11, . | 1.6 | 7 |
| 166 | Increased leucocyte apoptosis in transfused Î²â€thalassaemia patients. British Journal of Haematology, 2013, 160, 399-403. | 1.2 | 7 |
| 167 | Effect of automated red cell exchanges on oxygen saturation on-air, blood parameters and length of hospitalization in sickle cell disease patients with acute chest syndrome. Nigerian Medical Journal, 2016, 57, 190. | 0.6 | 7 |
| 168 | Evaluation of Deferasirox (ExjadeÂ®, ICL670) Therapy in Patients with Transfusional Iron Overload Who Achieve Serum Ferritin (SF) â‰1000 ng/mL in Long-Term Studies.. Blood, 2007, 110, 3795-3795. | 0.6 | 6 |
| 169 | Safety of Deferasirox (ExjadeÂ®) in Patients with Transfusion-Dependent Anemias and Iron Overload Who Achieve Serum Ferritin Levels <1000 Ng/Ml during Long-Term Treatment. Blood, 2008, 112, 5423-5423. | 0.6 | 6 |
| 170 | Liver iron measurement by MRI. Blood, 2005, 105, 437-438. | 0.6 | 5 |
| 171 | Clinical Evaluation of Deferasirox (ExjadeÂ®, ICL670). Seminars in Hematology, 2007, 44, S16-S20. | 1.8 | 5 |
| 172 | Influence of patientâ€reported outcomes on the treatment effect of deferasirox filmâ€coated and dispersible tablet formulations in the ECLIPSE trial: A post hoc mediation analysis. American Journal of Hematology, 2019, 94, E96-E99. | 2.0 | 5 |
| 173 | Effect of Ljpc-401 (synthetic human hepcidin) on Iron Parameters in Healthy Adults. Blood, 2018, 132, 2336-2336. | 0.6 | 5 |
| 174 | Efficacy and Safety of Deferasirox (ExjadeÂ®) in Patients with Î²-Thalassemia Major Treated for up to 5 Years.. Blood, 2009, 114, 4063-4063. | 0.6 | 5 |
| 175 | Residual Erythropoiesis Protects Against Cardiac Iron Loading in Transfusion Dependent Thalassaemia (TDT) By Lowering Labile Plasma Iron (LPI) through Transient Apotransferrin Generation. Blood, 2015, 126, 539-539. | 0.6 | 5 |
| 176 | Evaluation of Iron Levels to Avoid the Clinical Sequelae of Iron Overload. Seminars in Hematology, 2007, 44, S2-S6. | 1.8 | 4 |
| 177 | Efficacy and Safety of Deferasirox (ExjadeÂ®) in Î²-Thalassemia Patients with Myocardial Siderosis: 2-Year Results From the EPIC Cardiac Sub-Study.. Blood, 2009, 114, 4062-4062. | 0.6 | 4 |
| 178 | Clinical Use of Iron Chelators. , 2012, , 591-627. | | 3 |
| 179 | Impact of Dose Adjustments on Serum Ferritin (SF) Levels during Long-Term Treatment with Once-Daily, Oral Deferasirox (ExjadeÂ®, ICL670).. Blood, 2007, 110, 2778-2778. | 0.6 | 3 |
| 180 | Impact Of Liver Iron Overload On Myocardial T2* Response In Transfusion-Dependent Thalassemia Major Patients Treated With Deferasirox For Up To 3 Years. Blood, 2013, 122, 1016-1016. | 0.6 | 3 |

| # | Article | IF | Citations |
|---|---|---|---|
| 181 | Transfusion and Iron Chelation Therapy in Thalassemia and Sickle Cell Disease. , 2009, , 689-744. | | 2 |
| 182 | Introduction. Blood Reviews, 2009, 23, S1. | 2.8 | 2 |
| 183 | Secondary Erythrocytosis Due to Compound Homozygosity, but not Compound Heterozygosity, for Hb Luton and Î±-Thalassemia: A Family Study. Hemoglobin, 2012, 36, 7-17. | 0.4 | 2 |
| 184 | Iron in Haemoglobinopathies and Rare Anaemias. Thalassemia Reports, 2014, 4, 4859. | 0.1 | 2 |
| 185 | Myocardial iron quantification using T2* and native T1mapping - a 250 patient study. Journal of Cardiovascular Magnetic Resonance, 2015, 17, P312. | 1.6 | 2 |
| 186 | Predicting serum ferritin levels in patients with iron overload treated with the filmâ€coated tablet of deferasirox during the ECLIPSE study. American Journal of Hematology, 2019, 94, E15-E17. | 2.0 | 2 |
| 187 | Disease Specific Modulation of Serum Hepcidin: Impact of GDF-15 and Iron Metabolism Markers in Thalassemia Major, Thalassemia Intermedia and Sickle Cell Disease: A Univariate and Multivariate Analysis.. Blood, 2008, 112, 3850-3850. | 0.6 | 2 |
| 188 | Iron status influences the response of cord blood megakaryocyte progenitors to eltrombopag inÂvitro. Blood Advances, 2022, 6, 13-27. | 2.5 | 2 |
| 189 | An openâ€label, multicenter, efficacy, and safety study of deferasirox in ironâ€overloaded patients with nonâ€transfusionâ€dependent thalassemia (<scp>THETIS</scp>): 5â€year results. American Journal of Hematology, 2022, 97, . | 2.0 | 2 |
| 190 | Superior Vena Cava Occlusion by Cardiovascular Magnetic Resonance. Circulation, 2010, 122, 853-853. | 1.6 | 1 |
| 191 | Hemoglobinopathies in Pregnancy. , 2012, , 197-217. | | 1 |
| 192 | Normalized Left Ventricular Volumes and Function in Thalassemia Major Patients with Normal Myocardial Iron.. Blood, 2005, 106, 2707-2707. | 0.6 | 1 |
| 193 | Cell cycle synchronisation by 3-hydroxypyridin-4-one iron chelators. Cytotechnology, 1996, 18, 127-133. | 0.7 | 0 |
| 194 | Technical Report: Triple-Colour Staining Flow Cytometry for Co-Distribution of Thrombospondin Receptor (CD36), Ribonucleic Acid (RNA) and Fetal Haemoglobin (HbF) in Sickle Red Blood Cells. Hematology, 2001, 6, 91-100. | 0.7 | 0 |
| 195 | Trauma Induced Inflammation, Sepsis and Ageing. Ageing International, 2014, 39, 243-258. | 0.6 | 0 |
| 196 | Symptomatic Erythrocytosis Due to Homozygosity for Hb Luton [HBA2: c.269A>T (orHBA1)] andÎ±-Thalassemia: A Clinical Update. Hemoglobin, 2016, 40, 127-129. | 0.4 | 0 |
| 197 | Hydroxyurea Treated Sickle Disorders Demonstrate Decreased Plasma Hb, Red Cell Vesicles and Thrombolysis.. Blood, 2005, 106, 2322-2322. | 0.6 | 0 |
| 198 | The Effects of 24 Hour Continuous Deferoxamine Intensification on Serum Creatinine.. Blood, 2008, 112, 1851-1851. | 0.6 | 0 |

| # | Article | IF | Citations |
|---|---|---|---|
| 199 | Response to Cabantchik and Hershko commentary â€œPlasma nontransferrin bound ironâ€“nontransferrin bound iron revisited: Implications for systemic iron overload and in iv iron supplementationâ€. American Journal of Hematology, 2022, 97, . | 2.0 | 0 |